Avant Diagnostics, Inc.’s ("AVANT")(AVDX) data-generating technology allows patient-focused precision medicine to become a reality in cancer treatment.  Both pharmaceutical companies developing drugs and oncologists find that Avant’s Theralink® assay enables clear decision making on the effectiveness of drugs for an individual patient’s cancer treatment.

Cancer Tumor Biomarker Profiling: Driving Innovation in Personalized Medicine

At Avant Diagnostics, our approach is based on more than 16 years of research and development. In our experience, we have found that genetic information alone is insufficient to make patient specific treatment recommendations. Our phospho-proteomic approach, which focuses on measuring the quantity and intensity of drug target activation in the tumor tissue following standard biopsy procedures, exploits our understanding of drug-receptor interaction that is the driver of treatment response . Our advanced technology is being developed to guide physicians toward therapies that are most likely to lead to positive responses to treatment. Our large panel of markers targeted at already approved FDA drugs, as well as certain investigational therapies, makes Theralink® an invaluable tool for oncologists and pharmaceutical clinical trials.

Enabling Early and Late Stage Drug Development for Pharmaceutical and Biotechnology Companies

Avant Diagnostics’ Pharma Services Business will help drug companies accelerate their drug discovery programs and facilitate development of companion diagnostics. Avant’s data-generating technologies will also:

  • Stratify subjects entering clinical trials (reduces trial costs with smaller cohorts)
  • Monitor on and off target drug effects
  • Quantify phosphoproteome to identify activation of resistance or compensatory pathways post-treatment
  • Evaluate potential proteomic markers for combination therapies
  • Repurpose existing therapies for new indications (off-patent drugs and market expansion)

Enabling Physicians to make Personalized Treatment Recommendations for Cancer Patients

Avant provides personalized medicine data through its TheraLink® assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders, for over 70 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across multiple cancer types, including breast, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Theralink®, was developed to empower community physicians and clinical trial investigators with actionable information to make time sensitive treatment decisions for their patients. Theralink® was designed to inform physicians which treatments are likely to be effective for their patients at any given moment in time, and also identify which treatments are unlikely to be effective. This information has the potential to improve treatment efficacy and reduce side effects by foregoing ineffective therapy.

Science Backed by Strong Leadership

Meet the team that is the driving force behind our success.

View Management Team »